Eli Lilly beats Q3 earnings expectations with $17.6B revenue as Zepbound and Mounjaro drive growth. The Company raises full-year forecast amid booming weight-loss drug market.
Merck cuts 2025 revenue guidance and misses key drug sales targets in Q3, while preparing for Keytruda patent expiration and navigating tariff threats and China vaccine issues.
Novo Nordisk offers $77.75/share for Metsera in $9B deal, beating Pfizer's bid. Two-step structure includes immediate $56.50 dividend + milestone payments.
Novo Nordisk makes higher bid for Metsera to outbid Pfizer's $4.9B deal. Learn why this obesity drug startup is sparking a bidding war between pharmaceutical giants.
Intellia Therapeutics (NTLA) shares drop 15% after FDA halts late-stage gene therapy trials following serious liver safety concerns in patient.
Guardant Health reports 39% revenue growth in Q3 2025, narrows losses, and increases full-year guidance to $965-970M driven by oncology expansion and Shield screening test adoption.
